Question explored with the scientific record
was the covid vaccine harmful?
The COVID-19 vaccines caused real, documented harm to specific groups, but the evidence also shows they prevented far more harm from the virus itself.
The most clearly proven harm is myocarditis, an inflammation of the heart muscle. In young males aged 12-29, the risk after an mRNA vaccine was substantially higher than the background rate. A large study found the incidence of myocarditis was 50 to 139 cases per million in male adolescents and 28 to 147 per million in male young adults [4]. The risk was highest in the week after the second dose [4, 3]. Moderna's vaccine carried a higher risk than Pfizer's [4, 3, 2]. Beyond the heart, the adenovirus vaccines (AstraZeneca, Johnson & Johnson) caused a rare but severe clotting disorder called VITT, with a fatality rate of roughly 20-50% in reported cases [7, 9]. The systematic review of immune-mediated adverse events found 237 cases of thrombotic thrombocytopenic purpura (51.5% of all adverse events studied) and 33 cases of intracranial hemorrhage [8]. These are not mild side effects.
However, the evidence is also clear that the disease itself is more dangerous. The UK study showed that the risk of venous thromboembolism after a COVID-19 infection was 13.86 times higher than baseline, compared to a modest 1.1 times higher after the AstraZeneca vaccine [9]. A meta-analysis found the relative risk of myocarditis was about seven times higher from infection than from mRNA vaccination [1]. The net benefit at the population level is reflected in the large Norwegian study of 4.6 million adults, where people who received three or more mRNA doses had a roughly 58% lower adjusted all-cause mortality rate than the unvaccinated [5]. The Danish study of heart failure patients also found a lower 90-day mortality risk in the vaccinated group [6].
| Outcome | Approximate Risk / Effect | Key Evidence |
|---|---|---|
| Myocarditis (young males, mRNA) | 28-147 cases per million [4] | High after 2nd dose, especially Moderna [3, 4] |
| VITT (adenovirus vaccines) | ~0.4 per million [7] | Severe clotting, high mortality in reported cases [9] |
| Clot risk (infection vs vaccine) | Infection: 13.9x baseline; AZ vaccine: 1.1x [9] | Infection risk is far higher |
| All-cause mortality (3+ doses) | ~58% lower adjusted rate in vaccinated [5] | Large Norwegian cohort study |
My call: the COVID-19 vaccines did cause serious harm to a small number of people, primarily young males from mRNA vaccines and individuals from adenovirus vaccines, but the evidence consistently shows the vaccines reduced the far larger risks of severe illness, long-term complications, and death from COVID-19 infection. Confidence: high.
Sources used 9
-
Myocarditis after COVID-19: Comparing risks from vaccination and infection
A meta-analysis and FDA reports show COVID-19 infection carries a higher risk of myocarditis and more severe outcomes than mRNA vaccination, so vaccine benefits outweigh risks.
DOI: 10.47391/jpma.32162 -
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis
COVID-19 mRNA vaccination clearly outweighs the rare risk of myocarditis and pericarditis; incidence is about 1-4 per 100,000, mainly in young males after the second dose, and COVID-19 itself poses a much larger myocarditis risk.
DOI: 10.1007/s12471-022-01677-9 -
Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines
This study investigates the age and sex-specific risks of myocarditis and pericarditis following Covid-19 mRNA vaccinations, revealing significantly increased risks particularly after the second dose, especially in younger males.
DOI: 10.1038/s41467-022-31401-5 -
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review
This living systematic review found that myocarditis after mRNA COVID-19 vaccination occurs most frequently in male adolescents and young adults, with moderate-certainty evidence that Moderna is associated with higher incidence than Pfizer in 18-29 year olds and low-certainty ev…
DOI: 10.1136/bmj-2021-069445 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Risk of worsening heart failure and all-cause mortality following mRNA COVID-19 vaccination in patients with heart failure: a Danish nationwide real-world safety study
In a nationwide Danish cohort of 101,786 patients with heart failure, SARS-CoV-2 mRNA vaccination was associated with a lower 90-day all-cause mortality risk compared with a matched 2019 unvaccinated cohort and with no difference in worsening heart failure, myocarditis, or venou…
DOI: 10.1093/eurheartj/ehac544.881 -
Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination
Describes adverse thrombosis and thrombocytopenia after adenovirus-vectored COVID-19 vaccines using the WHO VigiBase database, discusses underlying mechanisms involving PF4 antibodies and HIT-like VITT, and notes these events are extremely rare while outlining countermeasures.
DOI: 10.1177/10760296211040110 -
Immune-mediated adverse events post-COVID vaccination and types of vaccines: a systematic review and meta-analysis
This systematic review and meta-analysis evaluates 34 studies involving 460 cases of immune-mediated adverse events following COVID-19 vaccination, highlighting the varying adverse profiles associated with different vaccine types.
DOI: 10.1186/s43162-022-00129-5 -
COVID-19 vaccination–related cardiovascular complications
This narrative review finds COVID-19 vaccination is associated with rare cardiovascular complications, especially mRNA vaccine myocarditis in young men and adenoviral vaccine VITT/VTE, but myocarditis and thrombosis are more common after SARS-CoV-2 infection and benefits outweig…
DOI: 10.36011/cpp.2023.5.e17